Pharmaceutical Executive Warren Whitehead Joins Amorfix as Chief Financial Officer
TORONTO, Jan. 31, 2013 /CNW/ - Amorfix Life Sciences Ltd. announced today that Mr. Warren Whitehead has joined the Company as Chief Financial Officer effective February 1, 2013. Janet Clennett will continue on as part of the management team and will assume the position of Director of Finance.
Mr. Whitehead has been in the pharmaceutical industry for more than 25 years and has previously held top management positions in a number of leading private and publicly owned pharmaceutical companies. Prior to joining Amorfix, Mr. Whitehead was CFO at Arius Research Inc., where he provided financial guidance and leadership during the acquisition of ARIUS by Roche in 2008 and prior to that he was CFO at Labopharm, Inc. where he completed a series of public equity financings and a NASDAQ IPO. He is currently a member of the Board of Directors of PlantForm Corporation and of Lorus Therapeutics.
"We are pleased to have such an experienced financial executive join the senior management at Amorfix", said Dr. Robert Gundel, Amorfix President and Chief Executive Officer. "Mr. Whitehead's financial expertise and his vast experience in both the biotechnology industry and the financial sector will provide the necessary leadership to advance our products through to commercialization, while maximizing returns to our shareholders".
Dr. Neil Cashman, Amorfix founder and Chairman of the Board said, "On behalf of the Board of Directors, I would like to thank Janet Clennett for all of her hard work and dedication to Amorfix over the past few years and we are pleased that Ms. Clennett will remain as a valuable member of the Amorfix management team in her new role. We welcome Mr. Whitehead to the Company and look forward to working with him as part of the management team."
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product development company developing therapeutic antibodies and diagnostics targeting misfolded protein diseases. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this technology, Amorfix is developing novel antibody therapeutics and companion diagnostics for cancer and amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample: Epitope Protection™ and AMFIA™, an ultra-sensitive dual-bead immunoassay. Use of these technologies has generated a cerebrospinal fluid (CSF) screening test for both Alzheimer's disease (AD) and mild cognitive impairment (MCI), and an ultrasensitive method for detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF and blood from animal models of AD. For more information about Amorfix, visit www.amorfix.com.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life Sciences Ltd.
SOURCE: Amorfix Life Sciences Ltd.For further information:
Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899